Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/303537
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | The role of propranolol as a repurposed drug in rare vascular diseases |
Autor: | Cuesta, Ángel M. CSIC ORCID ; Gallardo-Vara, Eunate CSIC ORCID; Casado-Vela, Juan CSIC ORCID CVN; Recio-Poveda, Lucía ; Botella, Luisa María CSIC ORCID ; Albiñana, Virginia CSIC | Palabras clave: | Beta-adrenergic receptor antagonist Propranolol HIF Apoptosis Iinflammation Angiogenesis |
Fecha de publicación: | 11-abr-2022 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | International Journal of Molecular Sciences 23 (8) 4217 (2022) | Resumen: | Rare Diseases (RD) are defined by their prevalence in less than 5 in 10,000 of the general population. Considered individually, each RD may seem insignificant, but together they add up to more than 7000 different diseases. Research in RD is not attractive for pharmaceutical companies since it is unlikely to recover development costs for medicines aimed to small numbers of patients. Since most of these diseases are life threatening, this fact underscores the urgent need for treatments. Drug repurposing consists of identifying new uses for approved drugs outside the scope of the original medical indication. It is an alternative option in drug development and represents a viable and risk-managed strategy to develop for RDs. In 2008, the “off label” therapeutic benefits of propranolol were described in the benign tumor Infantile Hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has, in the last decade, shown increasing evidence of its antiangiogenic, pro-apoptotic, vasoconstrictor and anti-inflammatory properties in different RDs, including vascular or oncological pathologies. This review highlights the finished and ongoing trials in which propranolol has arisen as a good repurposing drug for improving the health condition in RDs. | Descripción: | 12 p.-2 fig.-1 tab. | Versión del editor: | https://doi.org/10.3390/ijms23084217 | URI: | http://hdl.handle.net/10261/303537 | DOI: | 10.3390/ijms23084217 | ISSN: | 1661-6596 | E-ISSN: | 1422-0067 |
Aparece en las colecciones: | (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
ijms_cuesta_2022.pdf | Artículo principal | 933,14 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
9
checked on 25-abr-2024
WEB OF SCIENCETM
Citations
6
checked on 24-feb-2024
Page view(s)
31
checked on 27-abr-2024
Download(s)
21
checked on 27-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons